A recent study suggests that using artificial intelligence to measure tumor size could reduce treatment failures by more than 70%.

IceCure Medical (ICCM) announced that interim results from the Company’s ICESECRET study of cryoablation for patients with small renal masses ...

The FDA has extended its review of the ProSense cryoablation system for early-stage breast cancer, with a decision expected ...

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

Fusion biopsy and patient follow-up with 3D mapping are the cornerstone of a successful Focal Therapy program. In line with ...

Cryoablation, the destruction of malignant cancer cells by freezing them, is increasingly becoming an alternative to having ...

PR Newswire CAESAREA, Israel IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel /PRNewswire/ -- IceCure Medi ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most ...

A new UCLA study has found that artificial intelligence could help doctors identify prostate cancer patients most ...

A new artificial intelligence tool could help doctors determine which prostate cancer patients are most likely to benefit ...

A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment ...